Long-term Exercise After Pulmonary Rehabilitation (LEAP): A Pilot Randomized Controlled Trial of Tai Chi in COPD

Marilyn L. Moy<sup>1</sup>, Peter M. Wayne<sup>2,3</sup>, Daniel Litrownik<sup>4</sup>, Douglas Beach<sup>5</sup>, Elizabeth S. Klings<sup>6</sup>, Roger B. Davis<sup>4</sup>, Adlin Pinheiro<sup>4</sup>, and Gloria Y. Yeh<sup>2,4</sup>

<sup>1</sup> Pulmonary and Critical Care Medicine Section, Department of Medicine, Veterans Administration Boston Healthcare System, Boston, MA, USA

<sup>2</sup> Osher Center for Integrative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

<sup>3</sup> Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA

<sup>4</sup> Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, USA

<sup>5</sup> Division of Pulmonary, Sleep and Critical Care Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

<sup>6</sup>The Pulmonary Center, Boston University School of Medicine, Boston, MA, USA

## **ONLINE SUPPLEMENT**

## **METHODS**

## **Eligibility Criteria**

Inclusion criteria were age > 40 years and COPD defined as either  $FEV_1$ /forced vital capacity ( $FEV_1$ /FVC) <0.70 or chest CT evidence of emphysema[1]. Participants must have completed a supervised PR program within 24 weeks prior to study entry, defined as having attended 65% of the program's sessions, with a minimum of 10 sessions and of at least 8 weeks duration.

Exclusion criteria included COPD AE requiring corticosteroids, antibiotics, emergency room visit or hospitalization within the past 2 weeks; hypoxemia on 6MWT (O<sub>2</sub> sat < 85% on oxygen); inability to ambulate; clinical signs of unstable cardiovascular disease (i.e. chest pain on 6MWT); severe cognitive dysfunction; non-English speaking; current regular practice of Tai Chi; lung cancer treated in the past 5 years; or unstable/untreated mental health issue that precluded informed consent or affected ability to participate in the intervention[2].

### **Secondary Outcome Measures**

#### HRQL, Dyspnea, Mood, Stress, Social Support, and Self-Efficacy

The disease-specific Chronic Respiratory Disease Questionnaire (CRQ) has been validated in COPD [3]. Four domains include dyspnea, fatigue, emotional function and mastery. Items are scaled on a 7-point modified Likert Scale, with higher scores indicating better HRQL[3]. The University of California, San Diego Shortness of Breath (UCSD SOB) Questionnaire assessed overall dyspnea. The 24-item instrument assesses dyspnea during usual physical activities and has a recall period of one week. Respondents rate symptoms on a 6-point scale from "not at all" to "maximally or unable to do because of breathlessness"[4]. The minimal clinically important difference is 5 units[5].

The Center of Epidemiology Studies-Depression Scale (CES-D) is a validated measure of psychological impairment, primarily depressive symptoms[6]. Participants report how often they experienced various symptoms during the past week using a 4-point ordinal scale. A score of <15 indicates no depression. The CES-D has high internal consistency (r=0.90) and a test-retest reliability of 0.51[6]. The Perceived Stress Scale (PSS) is a measure of the degree to which situations in one's life are appraised as stressful[7]. We used the 10-item version of this instrument which has been shown to have good reliability and validity. The Multidimensional Scale of Perceived Social Support (MSPSS) is a validated 12-item instrument to assess the degree of perceived social support provided in subscale areas of the subject's existing social network (family, friends, and significant others)[8]. The COPD self-efficacy scale (CSES) is a 34-item scale that assesses self-efficacy for managing breathing difficulties in certain situations, including times of negative affect, emotional arousal, physical exertion, respiratory illness, and weather-related or environmental barriers[9]. The Exercise Self-Efficacy scale by Resnick is a brief 9-item instrument that assesses one's confidence in being able to exercise in the face of certain physical, emotional or situational barriers[10].

### Physical Activity and Exercise Engagement

The Community Health Activities Model Program for Seniors (CHAMPS) Physical Activity Questionnaire for Older Adults assessed self-reported physical activity (PA)[11]. CHAMPS is a 41-item instrument validated in the elderly, which covers PA from several domains, including leisure, household, and occupational activity. The Omron HJ-720ITC, a

3

waist-mounted pedometer with on-instrument digital data presentation, objectively measured PA as daily step counts. It has been shown to accurately measure daily step counts in most persons with COPD[12,13]. Participants, whose pedometer captured at least 90% of manual step counts assessed on an in-clinic walk, were sent home to wear the Omron during waking hours for a 14-day monitoring period. Values for days with valid step counts (> 200 steps/day) were averaged. Weekly self-report exercise logs captured engagement in the assigned home exercise (practice frequency and duration of home exercise sessions) and all other PA. A composite measure of exercise engagement was calculated using total minutes of class time, home practice time, and other PA on the exercise logs.

#### **Other Data Collection**

*Pulmonary Function Test* Spirometry at baseline, 12, and 24 weeks was performed following American Thoracic Society standards for quality and reproducibility[14].

*Acute Exacerbations* We defined AEs as "a complex of respiratory symptoms (increased or new onset) of at least two of the following: cough, sputum, wheezing, dyspnea, or chest tightness lasting 3 or more days, requiring a course of treatment (5 or more days) with antibiotics or systemic steroids"[15]. Participants were interviewed in person or by telephone every 3 months using a structured questionnaire to query symptoms, use of corticosteroids and/or antibiotics, and hospitalizations. Participant reports were verified with medical records whenever possible.

# REFERENCES

1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347–65.

2. Moy ML, Wayne PM, Litrownik D, Beach D, Klings ES, Davis RB, et al. Long-term Exercise After Pulmonary Rehabilitation (LEAP): Design and rationale of a randomized controlled trial of Tai Chi. Contemp Clin Trials. 2015 Nov;45:458–67.

3. Schünemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement Properties and Interpretability of the Chronic Respiratory Disease Questionnaire (CRQ). COPD J Chronic Obstr Pulm Dis. 2005 Jan;2(1):81–9.

4. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest. 1998 Mar;113(3):619–24.

5. Kupferberg DH, Kaplan RM, Slymen DJ, Ries AL. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardpulm Rehabil. 2005 Dec;25(6):370–7.

6. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977 Jun;1(3):385–401.

7. Cohen S, Kamarck T, Mermelstein R. A Global Measure of Perceived Stress. J Health Soc Behav. 1983;24(4):385–96.

8. Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric Characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess. 1990 Dec;55(3–4):610–7.

9. Wigal JK, Creer TL, Kotses H. The COPD Self-Efficacy Scale. Chest. 1991 May;99(5):1193–6.

10. Resnick B, Jenkins LS. Testing the Reliability and Validity of the Self-Efficacy for Exercise Scale: Nurs Res. 2000 May;49(3):154–9.

 Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL. CHAMPS Physical Activity Questionnaire for Older Adults: outcomes for interventions: Med Sci Sports Exerc. 2001 Jul;1126–41.

12. Danilack VA, Okunbor O, Richardson CR, Teylan M, Moy ML. Performance of a pedometer to measure physical activity in a U.S. cohort with chronic obstructive pulmonary disease. J Rehabil Res Dev. 2015;52(3):333–42.

13. Moy ML, Collins RJ, Martinez CH, Kadri R, Roman P, Holleman RG, et al. An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial. Chest. 2015 Jul;148(1):128–37.

14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug 1;26(2):319–38.

15. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med. 2011 Aug 25;365(8):689–98.